CoChat

Mortality in rheumatoid arthritis: the impact of disease activity, treatment with glucocorticoids, TNFα inhibitors and rituximab

Open access

The DOI matches its Crossref record, with a small difference in title or year; 35 of the 36 references it cites were found in a registry or an index.

Abstract

OBJECTIVES: To investigate the impact of disease activity, the course of the disease, its treatment over time, comorbidities and traditional risk factors on survival. METHODS: Data of the German biologics register RABBIT were used. Cox regression was applied to investigate the impact of time-varying covariates (disease activity as measured by the DAS28, functional capacity, treatment with glucocorticoids, biologic or synthetic disease modifying antirheumatic drugs (DMARDs)) on mortality after adjustment for age, sex, comorbid conditions and smoking. RESULTS: During 31 378 patient-years of follow-up, 463 of 8908 patients died (standardised mortality ratio: 1.49 (95% CI 1.36 to 1.63)). Patients with persistent, highly active disease (mean DAS28 > 5.1) had a significantly higher mortality risk (adjusted HR (HRadj)=2.43; (95% CI 1.64 to 3.61)) than patients with persistently low disease activity (mean DAS28 < 3.2). Poor function and treatment with glucocorticoids > 5 mg/d was significantly associated with an increased mortality, independent of disease activity. Significantly lower mortality was observed in patients treated with tumour necrosis factor α (TNFα) inhibitors (HRadj=0.64 (95% CI 0.50 to 0.81), rituximab (HRadj=0.57 (95% CI 0.39 to 0.84), or other biologics (HRadj=0.64 (95% CI 0.42 to 0.99), compared to those receiving methotrexate. To account for treatment termination in patients at risk, an HRadj for patients ever exposed to TNFα inhibitors or rituximab was calculated. This resulted in an HRadj of 0.77 (95% CI 0.60 to 0.97). CONCLUSIONS: Patients with long-standing high disease activity are at substantially increased risk of mortality. Effective control of disease activity decreases mortality. TNFα inhibitors and rituximab seem to be superior to conventional DMARDs in reducing this risk.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1136/annrheumdis-2013-204021

Cites

35 of 35 references verified0 citation errors · 0 not checkable

Statistics

Figures

Figure 1 Flow chart of patients enrolled. Censored: patients who were in this study on 31 December 2011 but did not complete a follow-up period of 9 years since they were enrolled after January 2003. The follow-up time of these patients was censored at the last regular study visit. Dropouts: patients lost to follow-up.
Figure 1 Flow chart of patients enrolled. Censored: patients who were in this study on 31 December 2011 but did not complete a follow-up period of 9 years since they were enrolled after January 2003. The follow-up time of these patients was censored at the last regular study visit. Dropouts: patients lost to follow-up.CC BY-NC · PubMed Central
Figure 2 Five-year survival rates (in %) for patients with highly active disease (DAS28 scores >5.1 at ≥80% of the observation time (18% of patients) and low disease activity (DAS28 scores <3.2 for ≥80% of the observation time (9% of patients) CHD: coronary heart disease.
Figure 2 Five-year survival rates (in %) for patients with highly active disease (DAS28 scores >5.1 at ≥80% of the observation time (18% of patients) and low disease activity (DAS28 scores <3.2 for ≥80% of the observation time (9% of patients) CHD: coronary heart disease.CC BY-NC · PubMed Central

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 35 references

Research works printed but not linked: 2

  1. del Rincon, 2001, High incidence of cardiovascular events in a rheumatoid arthritis cohort not explained by traditional cardiac risk factors, Arthritis Rheum, 44, 2737, 10.1002/1529-0131(200112)44:12<2737::aid-art460>3.0.co;2-# · doi:10.1002/1529-0131(200112)44:12<2737::aid-art460>3.0.co;2-#
  2. Lautenschlaeger, 1997, [Comparative evaluation of a German version of the Health Assessment Questionnaire and the Hannover Functional Capacity Questionnaire], Z Rheumatol, 56, 144

Cited by

See all 352

Metadata

Authors
Listing, J., Kekow, J., Manger, B., Burmester, G.-R., Pattloch, D., Zink, A., & Strangfeld, A.
Affiliations
  • German Rheumatism Research Centre (DE)
  • Otto-von-Guericke-Universität Magdeburg (DE)
  • Friedrich-Alexander-Universität Erlangen-Nürnberg (DE)
  • Charité – Universitätsmedizin Berlin (DE)
Corresponding author
Listing, Joachim
Venue
Annals of the Rheumatic Diseases
Publisher
Elsevier BV
Published
2015-02
Volume
74
Issue
2
Pages
415-421
ISSN
0003-4967 (ISSN-L)
OpenAlex
W2131517206
Cited by
295
References
36
Citations by year
2026: 16 · 2025: 16 · 2024: 22 · 2023: 28 · 2022: 22 · 2021: 26 · 2020: 22 · 2019: 22 · 2018: 24 · 2017: 31 · 2016: 34 · 2015: 21
FWCI
18.05
Type
journal article
Language
en
Open access
Licence
Locations
  • Annals of the Rheumatic Diseases (publishedVersion, cc-by-nc)
  • Europe PMC (PubMed Central) (publishedVersion, cc-by-nc)
  • PubMed Central (publishedVersion, cc-by-nc)
  • PubMed (publishedVersion)
  • OPUS FAU (Kooperativer Bibliotheksverbund Berlin-Brandenburg (KOBV), on behalf of the Universitätsbibliothek Erlangen-Nürnberg) (submittedVersion, cc-by-nc)
Funders
  • Amgen
  • Bristol-Myers Squibb
  • Pfizer
  • Sanofi
  • Ludwig-Maximilians-Universität München
  • Julius-Maximilians-Universität Würzburg
  • Swedish Orphan Biovitrum
Topics
  • Health Sciences › Medicine › Rheumatology › Rheumatoid Arthritis Research and Therapies
  • Health Sciences › Medicine › Hematology › Autoimmune and Inflammatory Disorders Research
  • Health Sciences › Medicine › Complementary and alternative medicine › Natural Compounds in Disease Treatment
Keywords
rheumatoid arthritis, mortality, disease activity, DAS28, glucocorticoids, TNF-alpha inhibitors, rituximab, biologic DMARDs, methotrexate, functional capacity, comorbidities
MeSH terms
Rituximab, Aged, Arthritis, Rheumatoid, Female, Glucocorticoids, Humans, Male, Middle Aged, Tumor Necrosis Factor-alpha, Proportional Hazards Models, Antirheumatic Agents, Antibodies, Monoclonal, Murine-Derived

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Mortality in rheumatoid arthritis: the impact of disease activity, treatment with glucocorticoids, TNFα inhibitors and rituximab. https://app.cochat.ai/papers/10.1136/annrheumdis-2013-204021
The paper
Listing, J., Kekow, J., Manger, B., Burmester, G.-R., Pattloch, D., Zink, A., & Strangfeld, A. (2015). Mortality in rheumatoid arthritis: the impact of disease activity, treatment with glucocorticoids, TNFα inhibitors and rituximab. Annals of the Rheumatic Diseases. https://doi.org/10.1136/annrheumdis-2013-204021

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.